Rubius raises $120M series B

Rubius Therapeutics Inc. (Cambridge, Mass.) raised $120 million in an untranched series B round. Flagship Pioneering and undisclosed institutional investors participated.

Using its Red-Cell Therapeutics platform, the company engineers hematopoietic progenitors to produce therapeutic proteins of interest when the progenitors differentiate into red blood cells (see BioCentury Innovations, Jan. 7, 2016). ...